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Abstract
Background: MiRNAs are essential regulators of skeletal muscle development and homeostasis. To date, the role
and regulation of miRNAs in myogenesis have been mostly studied in tissue culture and during embryogenesis.
However, little information relating to miRNA regulation during early post-natal skeletal muscle growth in mammals
is available. Using a high-throughput miRNA qPCR-based array, followed by stringent statistical and bioinformatics
analysis, we describe the expression pattern and putative role of 768 miRNAs in the quadriceps muscle of mice
aged 2 days, 2 weeks, 4 weeks and 12 weeks.
Results: Forty-six percent of all measured miRNAs were expressed in mouse quadriceps muscle during the first
12 weeks of life. We report unprecedented changes in miRNA expression levels over time. The expression of a
majority of miRNAs significantly decreased with post-natal muscle maturation in vivo. MiRNA clustering identified 2
subsets of miRNAs that are potentially involved in cell proliferation and differentiation, mainly via the regulation of
non-muscle specific targets.
Conclusion: Collective miRNA expression in mouse quadriceps muscle is subjected to substantial levels of
regulation during the first 12 weeks of age. This study identified a new suite of highly conserved miRNAs that are
predicted to influence early muscle development. As such it provides novel knowledge pertaining to post-natal
myogenesis and muscle regeneration in mammals.
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Background
Skeletal muscle development (myogenesis) and homeosta-
sis are regulated by a continuum of external and internal
cell signals that activate or repress gene expression. These
processes are fine-tuned by the joint action of transcrip-
tion factors [1, 2], DNA methylation [3, 4], histone modifi-
cation [5] and non-coding RNAs that include micro
(miRNAs) and long (lncRNAs) forms [6, 7]. The role of
lncRNAs has been scarcely described when compared to
miRNAs; the latter playing an essential part in the control
of cellular processes via transcriptional regulation [8–12].
Our study is focussed on miRNAs, which are small
20–24 nucleotide non-coding RNA molecules. In
miRNA nomenclature, the species is denominated by
the first 3 letters of the miRNA; where hsa defines a hu-
man miRNA, mmu defines a mouse miRNA and dre de-
fines a zebrafish miRNA. MiRNAs bind to specific sites
on the 3’UTR of their target transcripts and repress their
translation into a functional protein [13–17]. This
repression predominantly occurs by degradation of the
target mRNA [15] but also by directly inhibiting protein
translation. In some cases, it has been reported that
miRNAs also stabilize their target mRNAs [18]. The
current estimation is that more than a third of the
mRNA pool possesses at least one miRNA target [19].
MiRNAs bind to mRNA 3’UTR regions on the basis of
partial or full sequence homology [11, 13] and putative
miRNA target sequences can be identified using freely
available bioinformatics tools [20–22]. MiRNAs play a
major role in the maintenance of skeletal muscle homeo-
stasis in health and disease conditions [23]. Over the last
decade, studies in tissue culture and embryogenic
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models have established that miRNAs are essential regu-
lators of myogenesis. However, the role and regulation
of miRNAs during post-natal skeletal muscle develop-
ment in mammals has not been comprehensively
described.
In mice, a rapid 7–8 fold increase in body mass occurs
during the first 3 weeks of post-natal life. About half of
this increase is due to accretion in skeletal muscle mass
[24]. Murine post-natal muscle growth almost exclu-
sively relies on an increase in the size of muscle fibres
(hypertrophy) rather than an increase in fibre number,
which ceases around birth [25, 26]. Post -natal murine
skeletal development consists of 2 main growth phases
with a transition around 3 weeks of age, as represented
in Fig. 1. In the first 3 weeks, muscle precursor cells
(also known as myoblasts or satellite cells) proliferate
and fuse with the rapidly elongating myofibres to pro-
vide new myonuclei (hyperplasia) (Fig. 1a) [26, 27]. From
3 to 8 weeks of age, rapid hypertrophy results in a 3-fold
increase in the myofibre size [26]. This increase in sarco-
plasmic volume continues until at least 14 to 28 weeks
of age [27]. Early autoradiography studies tracking the in
vivo kinetics of myoblast proliferation and fusion in
healthy muscles of mice aged 6–8 weeks confirmed that
most satellite cells were quiescent at this age [28]. The
reason for this striking transition from hyperplasia to
hypertrophy during muscle growth is not known and
has not been widely investigated in other species (dis-
cussed in [29]).
At the molecular level, mammalian myogenesis is a
finely regulated process controlled by a series of muscle
specific transcription factors known as myogenic
Fig. 1 Graphical representation of key events during postnatal skeletal muscle growth (a) and indication of different types of cell nuclei within
mature muscle tissue (b) a In mice, skeletal muscle post-natal development is comprised of 2 main growth periods. Until 3 weeks of age (left
panel), satellite cells proliferate, followed by the incorporation of newly generated myonuclei into myofibres, resulting in hyperplasia. The rate of
proliferation and fusion gradually declines during this period. After 3 weeks of age (right panel), the proliferation of satellite cells ceases and there
is no additional incorporation of myonuclei into the myofibres. Past 3 weeks of age, muscle growth therefore results from hypertrophy only. By
3 weeks of postnatal age, the neuromuscular junction (NMJ) and innervation have matured and the vascular system and the extra-cellular matrix
(ECM) are considered developed. b Longitudinal section of adult mouse limb muscle stained with haematoxylin and eosin. Histology shows that the
bulk of the mature myofibre is occupied by sarcoplasm filled with contractile proteins, with muscle nuclei located at the surface of the myofibre. The
interface with the interstitial connective tissue shows a blood vessel and various cell types within the extracellular matrix
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regulatory factors (MRFs). The early regulators myogenic
differentiation 1 (Myod1) and myogenic factor-5 (Myf5)
facilitate the commitment of satellite cells to the myo-
genic fate, while myogenin (Myog/Myf4) and myogenic
factor-6 (Myf6) are essential for muscle cell differenti-
ation and muscle fibre formation [30]. In addition, the
paired box transcription factors (Pax3/Pax7) act up-
stream of Myod1 to regulate the entry of satellite cells
into the myogenic programme [31, 32]. MiRNAs play a
role in multiple aspects muscle growth [33], including
development, metabolism and repair. MRFs are involved
in the transcriptional regulation of muscle enriched miR-
NAs (myomiRs), including miR-1, miR-133 and miR-
206, and regulatory feedback loops have been identified
between miRNAs and MRFs in muscle cells [26, 34–36].
Recently, our group reported the expression levels of
these 3 myomiRs during post-natal muscle growth [12].
Gene expression profiling of post-natal myogenesis re-
cently identified new genes involved in the regulation of
satellite cell activation, proliferation and fusion including
ephrin-related molecules. These findings suggest that
myomiRs and other miRNAs may regulate more targets
in skeletal muscle [37].
To date, the expression levels of a large range of
miRNAs in post-natal skeletal muscle development in
vivo has not been investigated. This study is the first
to examine the expression pattern of 768 miRNAs
and their putative gene targets and function during
post-natal development of the mouse quadriceps
muscle, specifically at 2 days as well as 2, 4 and
12 weeks of age.
Methods
Mouse muscle samples
All animals (male C57BL/6J normal mice) were obtained
from the Animal Resource Centre, Murdoch, Western
Australia. Mice were housed at the University of West-
ern Australia pre-clinical facility under standard condi-
tions, with ad libitum access to food and drinking water.
Experiments were conducted in strict accordance with
guidelines outlined in the National Health and Medical
Research Council Code of practice for the care and use
of animals for scientific purposes (2004), and the Animal
Welfare act of Western Australia (2002). All animal ex-
periments were approved by the Animal Ethics commit-
tee at the University of Western Australia (RA/3/100/
1436). Mice aged 2, 4 and 12 weeks (n = 6 per age group)
were sacrificed by cervical dislocation under terminal
anaesthesia (2%v/v Attane isoflurane, Bomac, Australia).
Eight 2-day old mice were sacrificed by decapitation,
and due to the small muscle size the hind limb muscles
from 2 animals were pooled, resulting in n = 4. All
muscles were dissected out and snap frozen in liquid
nitrogen before being stored at −80 °C.
RNA extraction and reverse transcription
Total RNA was extracted from the quadriceps muscle
using the miRNeasy miRNA and total RNA purification
kit (Qiagen Inc., Chadstone, VIC, Australia) according to
the manufacturer’s protocol. Total RNA concentration
was assessed using the Nanodrop1000 Spectrophotom-
eter (Thermo Fisher Scientific, Waltham, MA). For
miRNA analysis, RNA (350 ng) was reverse transcribed
using the Taqman microRNA Reverse Transcription
(RT) kit and Megaplex RT Primers, Rodent Pool A and
Pool B v3.0 (Life Technologies, Mulgrave, VIC,
Australia). The RT reaction consisted of 2.7 mM dNTP,
0.3 U/μL RNase inhibitor, 3 mM MgCl2, 10 U/μL Multi-
Scribe enzyme, 1x buffer and 1x primers. The RT condi-
tions consisted of 40 cycles of 16 °C for two min, 42 °C
for one min and 50 °C for two min, followed by 5 min at
85 °C to stop the reaction then cooled to 4 °C. For gene
analysis, first-strand cDNA was generated from 500 ng
RNA in 20 uL reaction buffer using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies); 1x
RT buffer and random primers, 8 mmol/L dNTP and
2.5 U/μL MultiScribe™ RT enzyme. The RT protocol
consisted of 10 min at 25 °C, 120 min at 37 °C, 5 min at
85 °C then cooled to 4 °C.
Single-strand DNA quantification
RNA was treated with DNase I Amplification Grade
(Life Technologies) and first-strand cDNA was generated
as described above. cDNA was then treated with RNase
H (Life Technologies) according to the manufacturer’s
protocol. Single-strand DNA was quantified using the
Quant it OliGreen ssDNA Assay Kit (Life Technologies)
according to the manufacturer’s instructions and used
for mRNA PCR normalization.
Real-time PCR
Real-time PCR was carried out using a Stratagene
MX3000 thermal cycler (Agilent Technologies, Santa
Clara, CA). mRNA levels were measured using 1x SYBR®
Green PCR Master Mix (Life Technologies) and 5 ng of
cDNA. The PCR conditions were 1 cycle of 10 min
at 95 °C; 40 cycles of 30 s at 95 °C, 60 s at 60 °C,
60 s at 72 °C; 1 cycle (melting curve) 60 s at 90 °C,
30 s at 55 °C, 30 s at 95 °C. mRNA levels were nor-
malized to cDNA input. All primers were used at a
final concentration of 300 nM. Primer sequences are
presented in Table 1.
MiRNA screening
MiRNA expression in the samples was assessed using
the TaqMan Array Rodent MicroRNA A + B Cards v3.0
(Applied Biosystems, Mulgrave, VIC, Australia). Collect-
ively, these cards allow for the accurate quantitation of
768 mouse and rat miRNAs. The cards also contain 3
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candidate endogenous controls that are specific to
mouse and can be used for normalisation and an irrele-
vant miRNA that serves as a negative control and en-
sures that there is no non-specific amplification of
targets. The results from the Megaplex were then ana-
lysed using ExpressionSuite Software v1.0 (Applied Bio-
systems) and the data were normalized using the global
normalization function included in the software, a
technique that more accurately represents biological
variation than a selected number of endogenous controls
[38, 39]. Global normalisation applies a constant scaling
factor to every measurement in a qPCR well, so that
they all have the same median intensity. Because a con-
stant scaling factor is applied, the global normalisation
does not change the relative expression of individual
miRNAs in each well, while accounting for biological
and methodological variations. For individual miRNA
expression levels, Ct values were then transformed
into arbitrary units (AU) using the following equation:
AU=(1/2)Ct1010 and expressed relative to the mean
value of the latest time point each miRNA was
expressed at.
Statistical analysis
A first exploratory analysis of the data revealed a large
number of miRNAs with outlier Ct values. Therefore,
robust regression (M-estimation with scale parameter
estimated using the median method) was used to esti-
mate the linear trend in Ct values with time. For miR-
NAs with no significant trend on time, Kruskal-Wallis’
test was used to compare Ct values between times.
Given the exploratory nature of the study, we chose not
to correct for multiple comparisons to minimize the risk
of false negative results.
With the aim of identifying groups of expression pat-
terns versus time, quadratic models including time and
time2 were adjusted using the same robust approach. A
hierarchical clustering algorithm based on the Ward’s
minimum variance criterion was used to group the pre-
dicted Ct profiles into clusters. All regression analyses
were performed with SAS software, version 9.3 (SAS
Institute, Cary, NC).
In addition to the regression models, the individual
expression levels of the MRFs, a subset of miRNAs
including some myomiRs as well as the top-ranked miR-
NAs of each cluster (see below) were calculated. Arbi-
trary unit values were analyzed using a one-way analysis
of variance (ANOVA) using GenStat v16 [40]. Diagnostic
plots of residuals and fitted values were checked to
ensure homogeneity of variance (a key assumption for
ANOVA). The significance level was set at p < 0.05.
Bioinformatics
For each selected cluster, the top cellular functions and
miRNA-mRNA target interactions were determined
using Ingenuity System Interactive Pathway Systems
(version 18488943). Stringency was set at ‘highly pre-
dicted’ and ‘experimentally validated’. The software uses
its own internal algorithm and other databases, includ-
ing TarBase, TargetScan and miRecords, as well as find-
ings published in the literature. Ingenuity pathway
analysis (IPA) was used to generate figures depicting the
relationship between miRNAs and predicted target
mRNAs involved in cell cycle and proliferation, cell
differentiation and organismal development. Individual
target predictions were made using miRwalk [22].
Results
MiRNA expression levels during skeletal muscle
development
The cut-off for the relevant level of expression of each
miRNA was set at Mean (Ct) < 32 for each specific time
point, as recommended by the manufacturer. Out of the
768 miRNAs measured, 415 (54%) were considered not
expressed in mouse quadriceps muscle and were there-
fore excluded from further analysis. 310 miRNAs (40%)
were expressed at all time points, 42 miRNAs (5%) were
expressed at 2 or 3 time points, while one miRNA
(0.1%) was expressed at the 2-day time point only
(Additional file 1).
Linear trends in Ct values were assessed using a robust
regression model. Out of the 310 miRNAs expressed at
all time points, 205 (66%) presented a significant linear
trend in their Ct values over time. For 150 miRNAs the
Ct values increased over time (i.e. their expression levels
logarithmically decreased), while for 55 miRNAs the Ct
values decreased over time (i.e. their expression levels
logarithmically increased). The top-50 positive slopes
Table 1 Details of mouse primers for PCR analysis
Gene GenBank accession # Forward primer (5’-3’) Reverse primer (5’-3’)
Myf5 NM_008656.5 CACCACAACCAACCCTAACCA ACTCTCAATGTAGCGGATTGC
Myf6 NM_008657.2 GGTACCCTATCCCCTTGCCA GGGAGTTTGCGTTCCTCTGA
Myod1 NM_010866.2 CTGCTTCTTCACGCCCAAA CTGGAAGAACGGCTTCGAAAG
MyoG NM_031189.2 TCCATCGTGGACAGCATCAC CAATCTCAGTTGGGCATGGTTT
Pax3 NM_008781.4 AAACCCAAGCAGGTGACAAC CTAGATCCTCCTCCTCT
Pax7 NM_011039.2 GAGTTCGATTAGCCGAGTGC GTCGGGTTCTGATTCCACAT
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and the 50 negative slopes are individually reported in
Fig. 2. A comprehensive list of all significant slopes is
displayed in Additional file 2.
The expression pattern of 37 miRNAs that did not
present a linear trend showed significant changes be-
tween times when applying a non-parametric test
(Kruskal-Wallis’ test; Additional file 3). Overall, 238 out
of 310 miRNAs (77%) displayed a significant change
over time.
Expression levels of myomiRs with time
MyomiRs are expressed in muscle cells (skeletal and
cardiac) [33, 41]. The individual expression levels of the
myomiRs mmu-miR-1-3p, mmu-miR-133a-3p and hsa-
miR-206 are reported in Fig. 3. MiR-133a and miR-1
both significantly increased with time (main effect of
time, p < 0.001 and p < 0.01, respectively), while miR-206
expression significantly decreased with time (main effect
of time, p < 0.001).
MiRNA clustering
MiRNA expression profiles were classified in 10 clusters
using the predicted Ct values from a robust quadratic
model (Additional file 4). The 2 clusters that presented
the largest changes in predicted Ct values over time (re-
ferred to as cluster A and cluster B) were considered to
have the highest biological relevance and were selected
for bioinformatics analysis (Fig. 4). Cluster A included
44 miRNAs that were moderately expressed, with Ct
values between 27 and 32 PCR cycles for the 2-day age
group. The typical Ct profile for this cluster corresponds
to expression levels that decrease during the first 4 weeks
of life and remain mostly stable from 4–12 weeks. In
contrast, cluster B included 28 miRNAs with higher
initial expression levels that were detected between 23
and 26 PCR cycles for the 2-day age group. Their pre-
dicted expression levels generally displayed a gradual
decrease over the whole period studied. The predicted
Ct values for all miRNAs from cluster A and B are
provided in Additional file 5.
Ingenuity system interactive pathway systems analysis
Core analysis was performed on all miRNAs comprised
in a specific cluster. “Cellular Development” and “Cellu-
lar Growth and Proliferation” were the 2 highest ranked
Molecular and Cellular Functions returned for cluster A,
with p-values respectively comprised between 3.49E-02
– 1.8E-03 and 3.49E-02 – 6.3E-05. In contrast, the miR-
NAs included in cluster B were significantly associated
with the regulation of Organismal Development (p =
3.62E-02 – 3.28E-07) and Skeletal and Muscular Disor-
ders (p = 7.5E-03 – 1.7E-03).
Target analysis was completed on all miRNAs included
in cluster A and cluster B (Additional file 6). A list of
predicted and validated mRNA targets for the 44 miR-
NAs from cluster A and the 28 miRNAs from cluster B
Fig. 2 Statistically significant slopes (ΔCt/ΔDays) estimated using a robust regression model. The top-50 significant positive slopes (upper panel)
and the top-50 significant negative slopes (lower panel) are represented. Positive slopes indicate that the expression of miRNAs decreases over
time. Negative slopes indicate that the expression of miRNAs increases over time
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was generated using Ingenuity software prediction algo-
rithms. Putative gene targets were considered for further
analysis if they were returned as either “highly predicted”
and/or “experimentally observed”. For each cluster, the list
of genes was then sorted on the basis of the molecular
pathways that were associated with each gene, and genes
were categorized using the following key words: “cell cycle
and proliferation”, “cell differentiation”, “organismal devel-
opment” and “skeletal muscle”. Cell cycle and organismal
development were the most highly ranked cellular pro-
cesses predicted to be targeted by the miRNAs in clusters
A and B. For cluster A, 7% and 5% of all predicted gene
targets were associated with cell cycle and organismal de-
velopment, respectively, while these categories both repre-
sented 3% of the genes predicted to be targeted by the
members of cluster B. Muscle specific genes only repre-
sented a very minor proportion of the predicted targets
for both clusters (Table 2).
Following this, the genes known to regulate cell cycle
and proliferation, cell differentiation and organismal
development were selected to generate the figures illus-
trating the predicted role of the top-ranked miRNAs of
each cluster in the proliferation, differentiation and de-
velopment signalling cascades during the first 12 weeks
of age (Fig. 5). The top-ranked miRNAs for clusters A
were mmu-miR-18a-5p, mmu–miR-31–5p, mmu-miR-
130b–5p, mmu-miR-199a–5p, mmu-miR-200c–5p and
mmu-miR-224–5p. The top-ranked miRNAs for cluster
B were mmu-miR-134–5p, mmu-miR-136–5p, mmu-
miR-214–3p and mmu-miR-295–5p.
Fig. 3 MyomiRs expression levels over time. Box-plots of miRNA expression levels of the myomiRs mmu-miR-1-3p (a), mmu-miR-133a-3p (b) and
hsa-miR-206 (c) in mouse quadriceps muscle at 2 days, 2 weeks, 4 weeks and 12 weeks after birth. **, main effect of time, p < 0.01. ***, main effect
of time, p < 0.001. The data are reported as mean ± SEM
Fig. 4 MiRNA clusters. X-axis: time [days], Y-axis: average predicted
Ct value of all miRNAs of cluster A and B under a quadratic model in
time (robust regression). The data are reported as mean ± standard
deviation (SD)
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Individual expression levels of the top-ranked miRNAs for
each cluster and muscle specific predicted targets
The individual expression levels of the top-ranked miR-
NAs of each cluster are depicted in Fig. 6 (a and b). For
each miRNA, individual predictions were conducted to
investigate putative muscle-specific gene targets includ-
ing Pax3, Pax7, Myog, Myod1, Myf5 and Myf6 (Table 3).
Of the 10 miRNAs of interest, 9 had at least one highly
predicted muscle-specific target.
Gene expression levels of myogenic regulatory factors
(MRFs) during skeletal muscle growth
The MRF genes, including Myod1, Myf5, Myf6 and Myog,
and Pax genes, including Pax3 and Pax7, are the 2 major
families of genes orchestrating the myogenesis process.
All the miRNAs identified in our screening were predicted
to target at least one of these genes. The gene expression
levels of Myod1, Myf5, Myf6, Myog, Pax3 and Pax7 were
assessed in the quadriceps muscle of male C57BL/6J mice
during post-natal muscle development (2 days to
12 weeks). Myog (73-fold), Myf5 (12-fold), Pax7 (6.3-fold)
and Myod1 (2.6-fold) displayed significant decreases be-
tween 2 days and 12 weeks after birth (main effect of time,
all p < 0.05). There was no effect of time on Myf6 and
Pax3 expression levels (Fig. 6c).
Discussion
In this study, we describe for the first time the collective
and individual expression patterns of a subset of 768
miRNAs in mouse quadriceps muscle tissue during the
first 12 weeks of post-natal life. We report unprece-
dented changes in the miRNA expression levels over
time, supporting the hypothesis that miRNAs play an
essential role in the regulation of cellular processes
underlying skeletal muscle formation and maturation.
Stringent statistical and bioinformatics analysis con-
firmed the putative role of these miRNAs in the regula-
tion of the proliferation, differentiation and development
pathways, mainly via the regulation of gene targets that
were not specifically linked to skeletal muscle, but to the
development of a variety of tissues. The additional gen-
etic regulation exerted by lncRNAs [12] falls outside the
scope of this study.
Over the last 2 decades, miRNAs have emerged as im-
portant regulators of molecular processes in cells in general
[8–11] and in skeletal muscle in particular [12, 23, 33].
MiRNA detection is commonly achieved using real-time
quantitative PCR, with commercially available PCR-based
miRNA arrays allowing the simultaneous quantification of
hundreds of miRNAs [42, 43]. While a lack of consensus
exists around the most suitable normalization strategy
for single miRNA PCR analysis [44], the use of PCR-
based miRNA arrays allows for the normalization of
the individual cycle threshold (Ct) values to the
geometric mean of the whole miRNA pool, a process
referred to as global normalization [45]. Global
normalization rules out the occurrence of false-positive
results due to a lack of stability of a single normalization
miRNA over different times and conditions. This advan-
tage is particularly relevant in a growth model as extreme
as the one used in this study.
MiRNAs can be specifically enriched in certain tissues
[46] and myomiR is the term referring to the miRNA
species that are highly expressed in skeletal and cardiac
muscle [41, 47]. These miRNAs are involved in the regu-
lation of all fundamental biological processes in the
muscle, including growth, development, metabolism and
repair [33]. MiR-1, miR-133a and miR-206 were amongst
the 3 first identified myomiRs, with miR-1 and miR-133a
being part of a bicistronic cluster on the same chromo-
some [36]. Their role in myogenesis has been well de-
scribed in vitro using gain— and loss-of-function
studies. MiR-1, miR-133a and miR-206 are highly con-
served between species. Our study respectively reported
a 4-fold and 3-fold increase in mmu-miR-1a-3p and
mmu-miR-133a-3p expression levels over the first
12 weeks of age. MiR-133a and miR-1 respectively
promote myoblast proliferation and differentiation via
the repression of Srf and Hdac4 [36]. In contrast, the ex-
pression of hsa-miR-206, an indirect activator of Myod1
[48], decreased by 40-fold between birth and 12 weeks
of age. Similar to miR-1, miR-206 promotes satellite cell
differentiation and suppresses cell proliferation by dir-
ectly targeting the Pax7 3’UTR [48], suggesting a re-
duced need to engage stem cells into the myogenic fate
during the later stages of muscle growth. This is in line
Table 2 Biological classification of predicted mRNA targets
Biological classification of predicted mRNA targets Cluster A
[number of targets, %]
Cluster B
[number of targets, %]
Cell cycle 56, 6.5% 15, 3.1%
Development 39, 4.5% 14, 2.9%
Differentiation 14, 1.6% 9, 1.9%
Skeletal muscle 2, < 0.5% 1, < 0.5%
Others 751, 87.1% 440, 91.8%
mRNA transcripts predicted to be targeted by the miRNAs members of cluster A and cluster B were grouped on the basis of the cellular functions they are
associated with (key words used: “cell cycle and proliferation”, “cell differentiation”, “organismal development” and “skeletal muscle”)
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Fig. 5 Graphical representation of the relationships existing between the top ranked miRNAs and their target genes. Top-ranked miRNAs for cluster A
(upper panel) and B (lower panel) and their predicted gene targets within the proliferation, cell cycle and organismal development pathways. Cell cycle
regulators are shown in orange. Cell development regulators are shown in blue. Cell differentiation regulators are shown in green
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with the in vivo pattern of cessation of satellite cell pro-
liferation and fusion by 3 weeks of age in mice [26].
Beyond the highly expressed myomiRs, we report that
46% of all measured miRNAs were expressed in mouse
quadriceps muscle over the first 12 weeks of life. The ex-
pression levels of a majority of miRNAs decreased with
age, as the incidence and amplitude of many regulative
processes become less important. Statistical analysis
followed by miRNA clustering allowed the isolation of 2
subsets of miRNAs displaying common expression pat-
terns that were selected for bioinformatics analysis. The
predicted expression levels of the members of cluster A
Fig. 6 Expression levels of the top-ranked miRNAs of cluster A (b) and B (b) and MRFs and Pax family members over time (c). a Box-plots of
miRNA expression levels of mmu-miR-18a-5p, mmu-miR-31-5p, mmu-miR-130b-3p, mmu-miR-199a-5p, mmu-miR-200c-3p, mmu-miR-224-5p in
mouse quadriceps muscle at 2 days, 2 weeks, 4 weeks and 12 weeks after birth. ***, main effect of time, p < 0.001. ****, main effect of time, p < 0.0001.
The data are reported as mean ± SEM. b Box-plots of miRNA expression levels of mmu-miR-134-5p, mmu-miR-136-5p, mmu-miR-214-3p, mmu-miR-
296-5p in mouse quadriceps muscle at 2 days, 2 weeks, 4 weeks and 12 weeks after birth. ***, main effect of time, p < 0.001. ****, main effect of time,
p < 0.0001. The data are reported as mean ± SEM. c Gene expression levels of Pax3, Pax7, Myod1, Myf5, Myf6 and Myog at 2 days, 2 weeks, 4 weeks and
12 weeks after birth were measured by qPCR. Gene expression data were normalized to single-strand DNA content. A main effect of time was reported
for Pax7, Myod1, Myf5, and Myog (all p < 0.05). The data are reported as mean ± SEM
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were below or close to the 32 Ct limit of detection be-
tween 4 and 12 weeks of age. These miRNAs may there-
fore be involved in the regulation of very early cell
processes, and conceivably play an even more important
role in pre-natal (foetal and embryonic) muscle forma-
tion and growth. Accordingly, cellular development,
growth and proliferation were the highest ranked mo-
lecular functions returned for cluster A. In contrast, the
members of cluster B were consistently expressed from
week 4 to week 12 and were strongly linked to organis-
mal development. This suggests that, in addition to the
development of the muscle fibre itself, these miRNAs
may regulate the development of other cell components
in the growing muscle tissue (see Fig. 1). Indeed, it is im-
portant to acknowledge that other cell types outside the
myofibre contribute to the dynamics of muscle growth.
These are associated with neuromuscular function
(nerves and Schwann cells), vascularization (endothe-
lium, smooth muscle and bone-marrow derived cells)
and formation of the extracellular matrix (ECM), whose
components are largely produced by fibroblasts [49].
While skeletal muscle fibres represent about 95% of the
volume of muscle tissue, much of this consists of sarco-
plasm containing large contractile proteins with rela-
tively sparse myonuclei (see Fig. 1b). Furthermore, the
number of nuclei associated with adult myofibres only
represent about half of all nuclei present in muscle tissue
[50, 51]. The other 50% of nuclei outside the myofibre
are within different types of mononucleated cells associ-
ated with the nervous and the vascular systems (see Fig.
1b), as well as the interstitial connective tissue contain-
ing various cells, including fibroblasts. Although in adult
muscle tissue, myofibres are patently the most transcrip-
tionally active cell type [52], the transcriptome activity of
muscle tissue includes the combined expression of the
myogenic nuclei, plus the various non-myogenic nuclei,
in a ratio that may vary with development. Thus, these
aspects must be considered when interpreting patterns
of gene expression, especially related to miRNAs. Finally,
other miRNAs from cluster B have also been signifi-
cantly associated with muscular disorders in adults, indi-
cating that these miRNAs are presumably more active at
the level of the post-natal than the pre-natal developing
muscle.
Sparse literature exists around the top-ranked miRNAs
identified in this study and their role in the cell prolifer-
ation and differentiation processes. Although not se-
lected for bioinformatics analysis in this study, the top-3
miRNAs displaying an increase in expression with age
were members of the miR-29 family of miRNAs (mmu-
miR-29a, rno-miR-29c# and mmu-miR-29c), supporting
the important role played by this miRNA cluster in the
myogenesis process. MiR-29a inhibition downregulates
MyoD and upregulates cyclin-dependent kinase 6 (Cdk6)
expression in C2C12 myoblasts, therefore delaying cell
differentiation [53]. In contrast, miR-29 is upregulated in
the muscle of aged when compared to young rodents.
Corroborating our findings, miR-29 electroporation into
the muscle of young mice suppressed cell proliferation
and accelerated aging [54]. Several additional gene tar-
gets have been identified for the miR-29 family of miR-
NAs, including Akt3 [55] and Ring1 and YY1 binding
protein (Rybp) [55], a negative regulator of myogenesis.
Amongst the top-ranked miRNAs of cluster A, mmu-
miR-199a– 5p (homologous to hsa-miR-199a–5p and
dre-miR-199a–5p) regulates myogenic differentiation
acting downstream of Srf; the latter targets multiple
differentiation and proliferation factors within the Wnt
signalling pathway. Hsa-miR-199a-5p expression is in-
creased in human dystrophic muscle and overexpressing
dre-miR-199a-5p in zebrafish muscle leads to major and
lethal disruption of the myofibers [56]. In line with our
Table 3 Predicted muscle-specific gene targets for the top-ranked miRNAs of cluster A and B
miR ID Cluster Highly predicted target Moderately predicted target Homology with human miRNA
mmu-miR-18a-5p A Pax7 hsa-miR-18a-5p
mmu-miR-31-5p A Pax3, Myf5, Pax7 hsa-miR-31-5p
mmu-miR-130b-3p A Myod1 hsa-miR-130b-3p
mmu-miR-199a-5p A Pax3 Pax7, Myod1 hsa-miR-199a-5p
mmu-miR-200c-3p A Myf5 hsa-miR-200c-3p
mmu-miR-224-5p A Myod1 Pax7 First nt different from hsa-miR-224-5p
mmu-miR-134-5p B Pax7 Myf5 hsa-miR-134-5p
mmu-miR-136-5p B Pax3 Myog Last nt different from hsa-miR-136-5p
mmu-miR-214-3p B Pax7 Pax3 hsa-miR-214-3p
mmu-miR-296-5p B Pax7 hsa-miR-296-5p
Muscle-specific gene targets for the top-ranked miRNAs of cluster A and B were predicted using the miRNA/gene prediction tool in miRwalk v.2.0 [22]. A target was
considered as “highly predicted” when returned positive by at least 3/4 prediction software and as “moderately predicted” when returned positive by 2/4 prediction
software. The last column displays the name of the corresponding human miRNA. All miRNAs identified in this study were perfectly or highly homologous between
mouse and human
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observations, hsa-miR-31-5p (homologous to mmu-miR-
31-5p) expression is increased in regenerating [57] and
dystrophic muscle [57, 58] and positively regulates the
proliferation of vascular smooth muscle cells [59]. Hsa-
miR-31-5p directly targets the 3’UTR of human Hdac4
and Nrf1 [60], as well an evolutionary conserved sequence
of dystrophin 3’UTR [61]. Therefore, it likely plays a
multifaceted role in the regulation of skeletal muscle de-
velopment. The other members of miRNA cluster A have
received little attention, especially in skeletal muscle. Hsa-
miR-18a-5p (homologous to mmu-miR-18a-5p) enhances
cell apoptosis in human keratinocytes in vitro [62] and
stimulates the protein expression of the vascular smooth
muscle cell differentiation markers Acta2 and Tagln [63]
and mmu-miR-224-5p negatively regulates mouse adipo-
cyte differentiation [64]. This suggests that mmu-miR-
18a-5p and mmu-miR-224-5p may play roles in the early
stages of the skeletal muscle tissue development, including
vascular and adipocyte differentiation.
In contrast, the top-ranked miRNAs of cluster B have
been relatively well described in skeletal muscle. Next-
generation sequencing (NGS) technology revealed that
mmu-miR-136-5p is decreased in gastrocnemius muscle
from mice aged 6 and 24 months [65] and targets Rybp.
This corroborates our results where mmu-miR-136-5p
expression levels decrease by close to 80-fold between
the age of 2 days and 12 weeks in mouse quadriceps
muscle. In porcine skeletal muscle, the homologous ssc-
miR-214-3p is highly expressed in the foetal stages (em-
bryonic day 90) when compared with post-natal levels
(post-partum day 120) [66]. This is in line with our find-
ings in mouse muscle, where expression levels at
12 weeks of age were 14-fold greater than at 2 days.
Mmu-miR-214-3p inhibits proliferation and promotes
differentiation of the immortalized C2C12 mouse myo-
genic cell line in vitro [67]. Supressing mmu-miR-214-
3p expression maintains C2C12 myoblasts in an active
cell cycle and inhibits myogenic differentiation [68]. Our
data also show that mmu-miR-214-3p is highly predicted
to target Pax7 and we propose that it may act as a nega-
tive regulator of myoblast proliferation in vivo by dir-
ectly regulating the Pax7/Myod1 pathway. Of interest,
all 4 top-ranked miRNAs in cluster B were predicted to
target one of the Pax gene family members with a high
degree of certainty, potentially indicating a similar role
for mmu-miR-134-5p, mmu-miR-136-5p and mmu-miR-
296-5p. Mmu-miR-296-5p overexpression almost totally
suppresses the utrophin-A protein in C2C12 myoblasts
[69]. Utrophin is a cytoskeletal protein with similarities
to dystrophin. Utrophin is initially expressed by all myo-
nuclei and is located around the entire sarcolemma dur-
ing foetal and early post-natal myofibre growth.
However, by 3 weeks of age, utrophin protein expression
is restricted to beneath the NMJ [70]. The expression
pattern observed for mmu-miR-296-5p (down regulated
by 25-fold between 2 days and 12 weeks of age) supports
a potential role as an utrophin suppressor during myofibre
maturation. Finally, mmu-miR-134-5p (down regulated by
close to 100-fold between 2 days and 12 weeks of age) has
not been described in skeletal muscle. It enhances differ-
entiation in mouse embryonic stem cells [71] and also
promotes cell proliferation while preventing the induction
of differentiation and apoptosis in neuronal progenitor
cells [72]. Whether mmu-miR-134–5p has a similar role
in the muscle remains to be elucidated.
This study is the first to assess the expression levels of
a large pool of miRNAs in an in vivo model of muscle
development. A similar array has been previously con-
ducted in a mouse model of muscle regeneration [73]
and several miRNAs, including mmu-miR-18a-5p, mmu-
miR-136-5p, mmu-miR-31-5p and mmu-miR-199a-5p,
were similarly regulated as observed in our study.
Muscle regeneration may display similarities with post-
natal muscle development, although adult skeletal
muscle tissue possesses quiescent stem cells that differ
from developing tissues in aetiology and properties [74].
Conclusion
In conclusion, collective miRNA expression is subjected
to substantial levels of regulation in mouse skeletal
muscle tissue over the first 12 weeks of age. This study
identified a suite of highly conserved miRNAs that are
predicted to control muscle cell proliferation and differ-
entiation pathways with a high degree of certainty. The
specific role of these miRNAs in skeletal muscle devel-
opment, maturation, function and disturbed homeostasis
now requires expansion to a range of muscles in a range
of species and experimental validation in vivo.
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